Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Levalbuterol HCl Clear all
Completed Phase 4 Interventional Results available

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

NCT02799784
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, TIO/OLO, Albuterol/salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Clearwater, Florida • Orlando, Florida • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)

NCT02414854
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo, Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
1,902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
116
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Gilbert, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

NCT00073827
View directory record Official record
Conditions
Asthma
Interventions
levalbuterol tartrate MDI, racemic albuterol MDI, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
63
States / cities
Homewood, Alabama • Mobile, Alabama • Corona, California + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol

NCT00685425
View directory record Official record
Conditions
Asthma, Bronchoconstriction
Interventions
Levalbuterol HFA MDI, Racemic Albuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
5
States / cities
Los Angeles, California • Signal Hill, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Results available

Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)

NCT03620747
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab SAR231893 (REGN668)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
35
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol

NCT00325767
View directory record Official record
Conditions
Mucociliary Clearance
Interventions
nebulized albuterol (2.5 mg/3ml/dose), nebulized levalbuterol (1.25 mg/3ml/dose), nebulized placebo (3ml/dose)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2006 · Synced Sep 5, 2026, 4:22 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects

NCT02150499
View directory record Official record
Conditions
Asthma
Interventions
levalbuterol tartrate HFA inhalation aerosol, placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
Up to 48 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
17
States / cities
St. Petersburg, Florida • DeKalb, Illinois • Nicholasville, Kentucky + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma

NCT02528214
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo, Oral corticosteroid therapy (prednisone/prednisolone), Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Los Angeles, California • Rolling Hills Estates, California • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT00665600
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Levalbuterol HCl, Albuterol Sulfate, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years to 99 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
20
States / cities
Carmichael, California • Spring Valley, California • Wheat Ridge, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma

NCT00073814
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol tartrate MDI, racemic albuterol MDI, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
45
States / cities
Montgomery, Alabama • Jonesboro, Arkansas • Corona, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Phase 4 Interventional Results available

Continuous Levalbuterol for Treatment of Status Asthmaticus in Children

NCT00124176
View directory record Official record
Conditions
Asthma
Interventions
Racemic albuterol (R+S albuterol), Levalbuterol (R albuterol)
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years to 18 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Sep 5, 2026, 4:22 PM EDT
Terminated Phase 4 Interventional Results available

A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients

NCT00819637
View directory record Official record
Conditions
Acute Asthma
Interventions
arformoterol (RR formoterol), placebo, levalbuterol
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

NCT00073840
View directory record Official record
Conditions
Asthma
Interventions
levalbuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
54
States / cities
Oxford, Alabama • Tucson, Arizona • Corona, California + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Not applicable Interventional Results available

A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation

NCT00583778
View directory record Official record
Conditions
Asthma
Interventions
ipratropium
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Levalbuterol Versus Racemic Albuterol in Asthma

NCT00667407
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol 1.25 mg, Racemic Albuterol Sulfate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
28
States / cities
Hoover, Alabama • Montgomery, Alabama • Encinitas, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects

NCT00583947
View directory record Official record
Conditions
Asthma
Interventions
arformoterol, levalbuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
2 Years to 11 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
14
States / cities
Beverly Hills, California • Orange, California • Savannah, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Phase 2 Interventional

A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma

NCT00684827
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI, Racemic Albuterol followed by levalbuterol HFA MDI
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
4
States / cities
Encinitas, California • Los Angeles, California • North Dartmouth, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 5, 2026, 4:22 PM EDT
Not yet recruiting Not applicable Interventional

Clearance in Primary Ciliary Dyskinesia

NCT07699302
View directory record Official record
Conditions
Primary Ciliary Dyskinesia, PCD
Interventions
Exercise, HS pretreatment with Exercise
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

NCT02573233
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma

NCT00685022
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI, Racemic Albuterol followed by levalbuterol HFA MDI
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
3
States / cities
Encinitas, California • North Dartmouth, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Dupilumab in Children With Uncontrolled Asthma

NCT02948959
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo, Asthma Controller Therapies, Asthma Reliever Therapies
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 11 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
18
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD

NCT00583986
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease, COPD
Interventions
Levalbuterol HFA MDI with top mounted actuation indicator
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
4 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Encinatas, California • Huntington Beach, California • Mesa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 5, 2026, 4:22 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 5, 2026, 4:22 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma

NCT00684866
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI, Racemic Albuterol followed by levalbuterol HFA MDI
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
11
States / cities
Madera, California • San Diego, California • Savannah, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 5, 2026, 4:22 PM EDT